We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current FRX market cap is 370.81M. The company's latest EPS is USD -0.5937 and P/E is -23.11.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 170k | 0 | 1.54M | 21.25M |
| Operating Income | -13.01M | -17.89M | -17.22M | -22.74M | -12.77M |
| Net Income | -12.78M | -18.11M | -17.35M | -23.71M | -16.05M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 14.15M | 31.42M | 22.41M | 26.94M | 26.86M |
| Total Liabilities | 2.27M | 2.35M | 6.64M | 29.51M | 38.49M |
| Total Equity | 11.88M | 29.07M | 15.77M | -2.57M | -11.62M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -9.06M | -15.6M | -14.22M | -18.06M | -17.14M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | -71k | 32.29M | 4.98M | 20.73M | 6.64M |
| Market Cap | 370.81M |
| Price to Earnings Ratio | -23.11 |
| Price to Sales Ratio | 17.45 |
| Price to Cash Ratio | 27.94 |
| Price to Book Ratio | -31.91 |
| Dividend Yield | - |
| Shares Outstanding | 27.03M |
| Average Volume (1 week) | 232 |
| Average Volume (1 Month) | 269 |
| 52 Week Change | 37.89% |
| 52 Week High | 15.43 |
| 52 Week Low | 9.27 |
| Spread (Intraday) | 0.42 (3.02%) |
| Company Name | Fennec Pharmaceuticals Inc |
| Address |
c/o labarge weinstein llp ottawa, ontario K2K 3G4 |
| Website | https://www.fennecpharma.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
